Alumis (Nasdaq: ALMS) and Acelyrin (Nasdaq: SLRN) have agreed to merge in an all-stock deal, creating a late-stage ...

Roche has reported positive results from its Phase III REGENCY trial of Gazyva (obinutuzumab) for the treatment of lupus ...

San Diegan biotech Viking Therapeutics (Nasdaq: VKTX) has announced plans to initiate late-stage clinical trials for its ...

The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for brensocatib for patients with ...

Bristol Myers Squibb reported stronger-than-expected earnings for the fourth quarter and full year of 2024, but rising ...

The 90 million euros ($94 million) raised by Orbis Medicines in a series A round was not January’s biggest venture investment ...

US pharma giant Pfizer (NYSE: PFE) today announced that Jeffrey Legos will join the company as chief oncology officer.

Shares in US retinal diseases specialist EyePoint Pharmaceuticals recovered from an early nosedive to close trading marginally higher on Wednesday.

Swiss drug developer Basilea Pharmaceutica reported that the sales of the antifungal Cresemba (isavuconazole) in Japan exceeded the threshold triggering the first sales milestone payment from its ...

US pharma major Eli Lilly today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial ...

Anglo-Swedish pharma major AstraZeneca beat analyst expectations in presenting its impressive latest financial results.

California, USA-based rare disease company Ultragenyx Pharmaceutical yesterday released new data demonstrating treatment with UX111 (ABO-102) AAV gene therapy led to a statistically-significant ...